PTEN protein, in contrast to the PI3K/AKT pathway, is only altered in a subset of prostate cancers [11,22], so our goal was to identify replacement phosphomarkers that could be more broadly informative about PI3K/AKT pathway activity states [22,23]. The gene discussed is PTEN; the disease is prostate carcinoma.